Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2010-06-21
2011-12-13
Ouspenski, Ilia (Department: 1644)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
Reexamination Certificate
active
08076140
ABSTRACT:
Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant Bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis. Such transfected cells exhibit maximal cell densities that equal or exceed the maximal density achieved by the parent cell lines. Transfected cells can also be pre-adapted for growth in serum-free medium, greatly decreasing the time required to obtain protein production in serum-free medium. In certain methods, the pre-adapted cells can be used for protein production following transformation under serum-free conditions. The method preferably involves eukaryotic cells, more preferably mammalian cells.
REFERENCES:
patent: 6586206 (2003-07-01), Dixit et al.
patent: 6635448 (2003-10-01), Bucciarelli et al.
patent: 6635802 (2003-10-01), Piedrahita et al.
patent: 6964199 (2005-11-01), Lee et al.
patent: 7531327 (2009-05-01), Goldenberg et al.
patent: 7537930 (2009-05-01), Goldenberg et al.
patent: 2003/0064510 (2003-04-01), Reff et al.
patent: 2003/0069201 (2003-04-01), Reed
patent: 2003/0219871 (2003-11-01), Enenkel et al.
patent: 2007/0092947 (2007-04-01), Goldenberg et al.
patent: 2009/0111143 (2009-04-01), Goldenberg et al.
patent: 00/73419 (2000-12-01), None
patent: 01/23592 (2001-04-01), None
patent: 01/66696 (2001-09-01), None
patent: 02/16590 (2002-02-01), None
patent: 02/40665 (2002-05-01), None
patent: 03/006607 (2003-01-01), None
patent: 03/040374 (2003-05-01), None
patent: 03/057866 (2003-07-01), None
patent: 03/083093 (2003-10-01), None
patent: 2005/065348 (2005-07-01), None
patent: 2007/015691 (2007-02-01), None
patent: 2007/015848 (2007-02-01), None
Arden et al., “Cell engineering blocks stress and improves biotherapeutic production”, Bioprocessing Journal, 3:23-28 (2004).
Arden et al., “Life and death in mammalian cell culture: strategies for apoptosis inhibition”, Trends Biotechnol. 22 (4):174-80 (2004).
Brenner et al., “Increased p16 expression with first senescence arrest in human mammary epithelial cells and extended growth capacity with p16 inactivation”, Oncogene 17:199-205 (1998).
Chang et al., “Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: Implications for carcinogenesis, senescence, and age-related diseases”, Proc. Natl. Acad. Sci. USA 97, 4291-6, 2000.
Deng et al., “Mono- and multisite phosphorylation enhances BcI2's antiapoptotic function and inhibition of cell cycle entry functions”, PNAS (101) 153-158, 2004.
Deng et al., “BcI2 retards G1/S cell cycle transition by regulating intracellular ROS”, Blood, vol. 102, No. 9, pp. 3179-3185, 2003.
Finzer et al., “The role of human papillomavirus oncoproteins E6 and E7 in apoptosis”, Cancer Lett 188, 15-24, 2002.
Fujita et al., “Overexpression of M-2 Improved Survival of COS-1 Cells and Enhanced Transient Protein Production”, J. Ferment. Bioeng. 82(6):589-591 (1996).
Fujita et al., “Reinforcing apoptosisresistance of COS and myeloma cells by transfecting with bcl2 gene”, Cytotechnology 25:25-33 (1997).
Geisse et al., “Eukaryotic expression systems: a comparison”, Protein Expr. Purif. 8(3):271-82 (1996).
Ghezzi et al., “Erythropoietin as an antiapoptotic, tissue-protective cytokine”, Cell Death Differ. 11 (Suppl. 1), s37-s44, Jul. 2004.
Gillies et al., “High-level expression of chimeric antibodies using adapted cDNA variable region cassettes”, J. Immunol. Methods 125:191 (1989).
Goldstein and Singal “Senescence of Cultured Human Fibroblasts: Mitotic Versus Metabolic Time”, Exp. Cell Res. 88, 359-64, 1974.
Jackson et al., “E6 proteins from diverse cutaneous HPV types inhibit apoptosis in response to UV damage”, Oncogene 19(4):592-8 (2000).
Javelaud et al., “Induction of p21Waf1/Cip1 by TNFa requires NF-kB activity and antagonizes apoptosis in Ewing tumor cells”, Oncogene 19, 61-8, 2000.
Lee et al., “Human papilloma virus type 16 E7 genes protect astrocytes against apoptotic and necrotic death induced by hydrogen peroxide”, Yonsei Med. J. 42, 471-9, 2001.
Lee et al. “Development of Apoptosis-Resistant Dihydrofolate Reductase-Deficient Chinese Hamster Ovary Cell Line”, Biotechnology & Bioengineering 82:872-76, 2003.
Lotem et al., “Regulation by bcl-2, c-myc, and p53 of Susceptibility to Induction of Apoptosis by Heat Shock and Cancer Chemotherapy Compounds in Differentiation-competent and -defective Myeloid Leukemic Cells”, Cell Growth & Differentiation, 4:41-47 (1993).
Mercille et al., “Apoptosis-Resistant E1B-19K-Expressing NS/0 Myeloma Cells Exhibit Increased Viability and Chimeric Antibody Productivity under Perfusion Culture Conditions”, Biotechnol. Bioeng. 63:529-543 (1999).
Petros et al., “Structural biology of the Bcl-2 family of proteins”, Biochim. Biophys. Acta. 1644(2-3):83-94 (2004).
Romanos et al., “Production of a phosphorylated GST:HPV-6 E7 fusion protein using a yeast expression vector and glutathione S-transferase fusions”, Gene, vol. 152, No. 1, pp. 137-138, 1995.
Schwartz et al., “In vitro Meylopoiesis Stimulated by Rapid Medium Exchange and Supplementation with Hematopoietic Growth Factors”, Blood 78(12):3155-61, 1991 (Abstract only).
Storey et al., “Papillomaviruses: death-defying acts in skin cancer”, Trends Mol. Med. 8(9):417-21 (2002).
Suzuki et al., “Establishing Apoptosis Resistant Cell Lines for Improving Protein Productivity of Cell Culture” Cytotechnology 23:55-59, 1997.
Tey et al., “BcI-2 mediated suppression of apoptosis in myeloma NS0 cultures”, J. Biotechnol. 79(2):147-59 2000).
Tey et al., “Influence of Bcl-2 on cell death during cultivation of a Chinese Hamster Ovary cell line expressing a chimeric antibody”, Biotechnol. Bioeng. 68: 31-43, 2000.
Vaux et al., “BcI-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells”, Nature 335, 440-2, 1988.
Yang et al., “Inhibitors Directed towards Caspase-1 and -3 Are Less Effective than Pan Caspase Inhibition in Preventing Renal Proximal Tubular Cell Apoptosis”, Nephron Exp. Nephrol. 2004;96:e39-e51.
Rossi et al., “A new mammalian host cell with enhanced survival enables completely serum-free development of high-level protein production cell lines”, Biotechnol Prog. May 2011;27(3):766-75.
Chang Chien-Hsing
Goldenberg David M.
Nordstrom Diane
Qu Zhengxing
Rossi Edmund A.
Immunomedics Inc.
Nakashima Richard A.
Ouspenski Ilia
LandOfFree
Mammalian cell lines for increasing longevity and protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mammalian cell lines for increasing longevity and protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mammalian cell lines for increasing longevity and protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4261837